查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372935

血友病治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、產品、治療、治療、地區和競爭細分

Haemophilia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Product, By Treatment, By Therapy, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 172 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球血友病治療市場價值為118.9 億美元，預計在預測期內將出現令人印象深刻的成長，到2028 年年複合成長率為6.27%。血友病是一種複雜的遺傳性疾病，會影響血液凝固過程，導致血栓異常形成。這種情況表現為自發性出血過多、容易瘀青、受傷、外科手術和牙科介入後長時間滲血。它是由特定凝血因子的遺傳性缺陷引起的，由於凝血蛋白不足而導致血液凝固受損。然而，隨著醫學科學的進步，可以選擇多種治療方法。這些措施包括藥物、替代療法以及注射凝血因子或血漿以恢復正常的血栓形成。血友病治療的主要目標是取代缺失的凝血蛋白並有效控制病情，以預防併發症並改善血友病患者的生活品質。

主要市場促進因素

血友病的盛行率日益增加

市場概況
預測期 2024-2028
2022 年市場規模 118.9億美元
2028 年市場規模 171.4億美元
2023-2028 年年複合成長率 6.27%
成長最快的細分市場 基因治療
最大的市場 北美洲

血泳是指血液對流或組織沖洗的過程。根據美國疾病管制與預防中心 (CDC) 的說法，血友病被歸類為一種影響血液正常凝固的「遺傳性出血性疾病」。疾病預防控制中心強調，這種情況可能導致自發性出血、受傷和手術後出血。值得注意的是，血液中含有多種被稱為凝血因子的蛋白質，它們在止血中起著至關重要的作用。血友病患者的因子 VIII (8) 或因子 IX (9) 水準降低。一個人所經歷的血友病的嚴重程度直接受到血液中這些因素的數量的影響。因子含量越低，出血的可能性就越高，這可能會導致嚴重的健康併發症。了解血友病的複雜細節對於為受此病影響的人提供適當的護理和支持至關重要。

新產品和藥物上市

血流療法是一種用於血液對流或組織沖洗的技術，在管理某些醫療狀況方面發揮著至關重要的作用。作為一項重大且突破性的進展，領先的生物技術公司Biomarin 最近分享了2022 年1 月進行的III 期臨床試驗的備受期待的結果。該試驗經過精心設計和執行，重點評估valoctocogener oxaparvovec 的有效性和潛力，一種有前途的基因療法，用於治療嚴重的血友病A。這項開創性的研究不僅帶來了希望，還為患有這種具有挑戰性和改變生活的疾病的個體帶來了新的、令人興奮的可能性。這項突破性發現有可能徹底改變血友病治療領域，標誌著醫學領域的一個重要里程碑，並為改善患者治療結果和提高生活品質鋪平了道路。

血友病抑制劑的成長

血友病抑制劑的成長無疑增加了血友病治療的需求，為醫療保健領域帶來了新的挑戰和機會。血友病是一種罕見的遺傳性疾病，其特徵是凝血功能受損，長期以來一直透過服用凝血因子濃縮物來控制。然而，血友病患者有很大一部分會產生抑制劑，即中和這些凝血因子的抗體。這種發展使治療變得複雜，因為傳統療法變得不太有效，導致出血事件增加和受影響個體的生活品質下降。

預防治療趨勢激增

預防性治療的激增趨勢顯著增加了對血友病治療的需求，標誌著這種複雜出血性疾病的護理和管理髮生了積極轉變。歷史上，血友病通常採用反應性治療，主要使用凝血因子濃縮物來控制出血事件。然而，預防治療（一種涉及定期輸注凝血因子的預防方法）的出現徹底改變了血友病照護的面貌。事實證明，預防性治療對於血友病患者，尤其是患有嚴重血友病的患者來說，可以改變遊戲規則。透過提供穩定的凝血因子供應，預防有助於維持血液中這些必需蛋白質的更高和更穩定的水平，從而顯著降低出血事件的頻率和嚴重程度。結果，患者的生活品質顯著改善，疼痛和關節損傷減少，參與日常活動和運動的能力更強。

這種向預防的典範轉移在多個方面對血友病治療的需求不斷成長。首先，對其有效性的日益認可導致醫療保健專業人員、患者和護理人員更大力倡導其採用。因此，越來越多的人尋求預防性治療，這給醫療保健系統帶來了更大的壓力，以確保凝血因子濃縮物和適當的護理基礎設施的可用性。

主要市場挑戰

血友病治療費用高昂

與血友病治療相關的高昂費用是一個重大阻礙，減少了受影響個體對適當護理的需求。血友病是一種罕見的遺傳性疾病，其特徵是凝血受損，需要定期輸注凝血因子濃縮物或其他專門治療來控制和預防出血事件。不幸的是，這些治療的經濟負擔可能對患者及其家人來說是巨大的，導致獲得護理的機會減少和健康結果不佳。血友病治療的費用是多方面的。它不僅包括凝血因子濃縮物的價格，還包括與住院、醫療設備、定期監測和相關藥物相關的費用。保險範圍對於許多患者獲得治療至關重要，但可能不會總是完全覆蓋這些費用，導致患者需要自付費用。此外，血友病治療的持續性加劇了財務壓力，因為患者需要終身護理和支持。

血友病治療的高昂費用導致獲得護理的機會存在差異，有些人在獲得必要的治療方面面臨障礙。這可能導致治療延遲或不充分，增加嚴重出血、關節損傷和其他併發症的風險。此外，經濟壓力也會對患者及其家人的整體福祉產生負面影響，導致壓力和焦慮。

發展中國家技術先進產品的採用率較低

發展中國家技術先進的血友病治療產品的採用率較低，這大大降低了受這種罕見出血性疾病影響的個人對適當護理的整體需求。血友病管理取得了顯著進步，包括重組凝血因子濃縮物、新型療法和攜帶式輸液設備的開發。然而，這些尖端治療方法的可近性和可負擔性在許多發展中國家仍然是一個挑戰，導致醫療保健差距擴大。

導致採用率低的主要因素之一是技術先進的血友病產品的高成本。這些創新療法通常價格昂貴，對於資源有限的環境中的個人和醫療保健系統來說在經濟上超出了承受能力。有限的保險範圍和公共資金進一步加劇了這個問題，使許多患者只能接受傳統且效果較差的治療選擇。

此外，發展中國家往往缺乏支持管理和監測高階血友病治療所需的基礎設施。這不僅包括提供專業醫療人員，還包括為需要定期護理的患者提供診斷設施和交通服務。如果沒有必要的基礎設施，先進療法的實施將成為一項艱鉅的挑戰。

主要市場趨勢

合作研究和藥物開發

製藥公司擁有開發和製造新療法的資源和專業知識。研究機構貢獻科學知識和創新，而患者組織則提供對血友病患者生活經驗的見解。透過共同努力，這些實體可以結合各自的優勢來應對複雜的挑戰。合作使研究人員能夠匯集他們的知識和資料，並加快研究進程。這可以更快地識別潛在候選藥物、簡化臨床試驗並加快法規核准速度。患者組織代表血友病患者的聲音和需求。他們的參與確保新的治療方法在設計時考慮到患者的喜好，從而提高治療依從性和整體滿意度。

合作可以促進患者參與實驗性治療的臨床試驗。患者組織通常在將符合資格的個人與這些機會聯繫起來方面發揮著至關重要的作用，確保臨床試驗參與者能夠代表患者群體。

基因治療的進展

血友病的基因治療是一個有前景且具有開創性的研究領域，有可能徹底改變血友病患者的治療模式。這種創新方法旨在透過將功能性凝血因子基因引入患者體內來解決病情的根本原因。隨著基因治療技術變得更加完善和成功，它們不僅提供了治療血友病的可能性，而且有可能治癒它，消除了終生輸注凝血因子的需要。與控制症狀的傳統療法不同，基因療法旨在改變導致血友病的潛在遺傳缺陷。透過將功能性凝血因子基因引入體內，有可能恢復自然產生凝血因子的能力。基因療法為血友病的預防提供了可能性，患者可能不再需要擔心出血事件，並且可以過著更正常、積極的生活。

雖然血友病的基因治療前景廣闊，但仍存在需要克服的挑戰，包括治療效果的長期安全性和持久性、更廣泛的可及性以及對基因治療載體的潛在免疫反應。然而，正在進行的研究和開發工作旨在解決這些挑戰，透過基因療法治癒血友病的潛力是一個令人興奮的前景，為受這種罕見出血性疾病影響的個人和家庭帶來了希望。

細分市場洞察

類型洞察

2022年，血友病A成為血友病市場的主導者，佔最高佔有率。這種遺傳性疾病的特徵是缺乏凝血因子 VIII，導致出血時間延長。 A 型血友病在已開發地區的流行，加上政府的支持舉措，有助於推動其市場主導地位。美國、歐洲、日本等主要市場紛紛推出創新產品，進一步鞏固了血友病A的市場地位。根據世界血友病聯合會（WFH）2020年的調查顯示，美國等國家、印度和巴西報告了大量A 型血友病病例，估計約10,000 例。這強調了迫切需要有效的治療和管理策略來解決這種複雜的遺傳性疾病。

另一方面，B 型血友病預計將在預測期內呈現穩定成長。這种血友病的特徵是缺乏凝血因子 IX。 B 型血友病的市場成長可歸因於強大的創新產品管線和基因療法的出現。值得注意的是，2023 年2 月，歐盟委員會有條件批准CSL Behring 的基因療法Hemgenix 用於治療B 型血友病。這一里程碑式的批准是在該產品成功在美國市場推出之後進行的，該產品在美國市場的售價為350 萬美元進行拋棄式治療。治療領域的這些進步為血友病患者帶來了光明的前景，為他們提供了生活品質的提升和疾病管理的選擇。

治療見解

根據治療類型，治療和血友病市場分為兩大類：預防和按需治療。按需治療（涉及在發生出血時給予藥物）在 2022 年佔據最大的市場佔有率。然而，預計預防領域在預測期內將經歷最高的成長率。

一種常用且廣泛接受的預防性治療形式是預防，包括定期注射凝血因子濃縮物。預防在治療嚴重血友病方面顯示出顯著療效，並有可能提高該市場的成長率。預防性治療的持續時間根據患者病情的嚴重程度而有所不同，其目的是減少血友病患者的生產力損失並提高整體生活品質。

透過提供一致且主動的方法來管理出血事件，預防性治療可望最大限度地減少血友病對患者日常生活的影響。它預防或減少出血事件的能力不僅可以改善身體健康，還可以對患有這種疾病的人的情緒和社交方面產生積極影響。

區域洞察

2022年，北美成為全球血友病治療市場的主導力量，緊隨其後的是歐洲。在美國，血友病的盛行率約為每 100 萬男性 134 例。血友病患病率不斷上升、醫療保健支出不斷增加、人們對出血性疾病的認知不斷提高、診斷技術和治療的廣泛研究和開發以及有利的報銷政策等因素極大地促進了北美血友病治療市場的成長。展望未來，亞太地區預計將在 2024 年至 2028 年的預測期內實現最高成長率。該地區的成長可歸因於血友病發病率的上升、對該疾病的認知的提高、可支配收入的增加以及醫療基礎設施的改善。值得注意的是，中國和印度等新興經濟體正在見證政府和研究機構為血友病診斷和治療進步提供的資金不斷增加，以及重組產品的使用不斷增加。這些因素共同為亞太市場帶來了利潤豐厚的機會。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球血友病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（血友病 A、血友病 B、血友病 C）
    • 依產品（重組凝血因子濃縮物、血漿衍生凝血因子濃縮物、去氨加壓素、抗纖維蛋白溶解劑）
    • 按治療（按需治療和預防治療）
    • 依治療方式（替代療法、ITI療法和基因療法）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美血友病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品分類
    • 按治療
    • 透過治療
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲血友病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品分類
    • 按治療
    • 透過治療
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區血友病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品分類
    • 按治療
    • 依治療方法 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲血友病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品分類
    • 按治療
    • 依治療方法 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲血友病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品分類
    • 按治療
    • 透過治療
    • 按國家/地區
  • MEA：國家分析
    • 南非血友病治療
    • 沙烏地阿拉伯血友病治療
    • 阿拉伯聯合大公國血友病治療

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球血友病治療市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Bayer AG
    • BioMarin Pharmaceutical, Inc.
    • CSL Behring LLC
    • Kedrion SpA
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Octapharma AG
    • Sanofi SA
    • Takeda Pharmaceutical Company
    • Grifols SA

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 16354

Global Haemophilia Treatment Market has valued at USD 11.89 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.27% through 2028. Hemophilia is a complex inherited medical disorder that affects the blood clotting process, leading to abnormal clot formation. This condition manifests as spontaneous and excessive bleeding, easy bruising, and prolonged oozing after injuries, surgical procedures, and dental interventions. It arises from a hereditary deficiency of specific coagulation factors, resulting in impaired blood clotting due to insufficient clotting proteins. However, with advancements in medical science, various treatment options are available. These include medications, replacement therapy, and injections of clotting factors or plasma to restore proper clot formation. The primary goal of hemophilia treatment is to replace the missing clotting proteins and effectively manage the condition to prevent complications and improve the quality of life for individuals with hemophilia.

Key Market Drivers

Increasing Predominance of Hemophilia

Market Overview
Forecast Period2024-2028
Market Size 2022USD 11.89 Billion
Market Size 2028USD 17.14 Billion
CAGR 2023-20286.27%
Fastest Growing SegmentGene Therapy
Largest MarketNorth America

Hemophoresis refers to the process of blood convection or the flushing of tissues. According to the Centers for Disease Control and Prevention (CDC), hemophilia is classified as a "hereditary bleeding disorder" that affects the proper coagulation of blood. The CDC emphasizes that this condition can result in spontaneous bleeding, injuries, and post-surgery bleeding. It is worth noting that blood contains various proteins known as coagulation factors, which play a crucial role in stopping bleeding. Individuals with hemophilia exhibit reduced levels of either factor VIII (8) or factor IX (9). The severity of hemophilia experienced by a person is directly influenced by the quantity of these factors present in their blood. The lower the amount of factor, the higher the likelihood of bleeding, which can potentially lead to significant health complications. Understanding the intricate details of hemophilia is vital in order to provide appropriate care and support to those affected by this condition.

New Products and Medication Launches

Hemophoresis, a technique used for blood convection or flushing of tissues, plays a crucial and vital role in managing certain medical conditions. In a significant and groundbreaking development, Biomarin, a leading biotechnology company, recently shared the highly anticipated outcomes of a phase III clinical trial conducted in January 2022. The trial, meticulously designed and executed, focused on evaluating the effectiveness and potential of valoctocogener oxaparvovec, a promising gene therapy, for the treatment of severe hemophilia A. This groundbreaking research not only provides hope but also brings forth new and exciting possibilities for individuals living with this challenging and life-altering condition. With the potential to revolutionize the landscape of hemophilia treatment, this breakthrough discovery marks a significant milestone in the field of medical science and paves the way for improved patient outcomes and better quality of life.

Growth in Hemophilia Inhibitors

The growth in hemophilia inhibitors is undeniably increasing the demand for hemophilia treatment, ushering in new challenges and opportunities in the field of healthcare. Hemophilia, a rare genetic disorder characterized by impaired blood clotting, has long been managed through the administration of clotting factor concentrates. However, a significant subset of hemophilia patients develops inhibitors, which are antibodies that neutralize these clotting factors. This development complicates treatment, as conventional therapies become less effective, leading to increased bleeding episodes and a reduced quality of life for affected individuals.

The rise in hemophilia inhibitors has spurred several noteworthy developments in the realm of hemophilia treatment. First and foremost, there is an intensified need for novel treatment approaches that can effectively manage hemophilia in patients with inhibitors. Researchers and pharmaceutical companies are now focusing on the development of bypassing agents, non-factor therapies, and gene therapy as promising alternatives. These innovations offer hope for those who previously faced limited treatment options.

Surging Trend Of Prophylaxis Treatment

The surging trend of prophylaxis treatment is significantly increasing the demand for hemophilia treatment, marking a positive shift in the care and management of this complex bleeding disorder. Historically, hemophilia was often treated reactively, with clotting factor concentrates administered primarily to control bleeding episodes. However, the advent of prophylaxis, a preventive approach involving the regular infusion of clotting factors, has revolutionized the landscape of hemophilia care. Prophylactic treatment has proven to be a game-changer for individuals with hemophilia, especially those with severe forms of the condition. By providing a steady supply of clotting factors, prophylaxis helps maintain higher and more stable levels of these essential proteins in the bloodstream, significantly reducing the frequency and severity of bleeding episodes. As a result, patients experience a notably improved quality of life, reduced pain and joint damage, and a greater ability to engage in daily activities and sports.

This paradigm shift toward prophylaxis has created a growing demand for hemophilia treatment on several fronts. Firstly, the increasing recognition of its effectiveness has led to greater advocacy for its adoption among healthcare professionals, patients, and caregivers. Consequently, more individuals are seeking prophylactic treatment, which places greater pressure on healthcare systems to ensure the availability of clotting factor concentrates and appropriate care infrastructure.

Key Market Challenges

High Cost Linked with Hemophilia Treatment

The high cost associated with hemophilia treatment is a significant deterrent that is decreasing the demand for proper care among affected individuals. Hemophilia, a rare genetic disorder characterized by impaired blood clotting, necessitates regular infusions of clotting factor concentrates or other specialized treatments to manage and prevent bleeding episodes. Unfortunately, the financial burden of these treatments can be overwhelming for patients and their families, leading to reduced access to care and suboptimal health outcomes. The cost of hemophilia treatment is multi-faceted. It encompasses not only the price of clotting factor concentrates but also expenses related to hospitalization, medical equipment, regular monitoring, and associated medications. Insurance coverage, which is essential for many patients to access treatment, may not always fully cover these expenses, leaving patients with significant out-of-pocket costs. Furthermore, the ongoing nature of hemophilia treatment compounds the financial strain, as patients require lifelong care and support.

The high cost of hemophilia treatment contributes to disparities in access to care, with some individuals facing barriers to obtaining the necessary therapies. This can lead to delayed or inadequate treatment, increasing the risk of severe bleeding episodes, joint damage, and other complications. Additionally, the financial strain can negatively impact the overall well-being of patients and their families, causing stress and anxiety.

Low Adoption Rates Of Technologically Advanced Products In Developing Countries

The low adoption rates of technologically advanced hemophilia treatment products in developing countries are significantly decreasing the overall demand for proper care among individuals affected by this rare bleeding disorder. Hemophilia management has seen remarkable advancements, including the development of recombinant clotting factor concentrates, novel therapies, and portable infusion devices. However, the accessibility and affordability of these cutting-edge treatments remain a challenge in many developing nations, leading to a widening healthcare disparity gap.

One of the primary factors contributing to the low adoption rates is the high cost associated with technologically advanced hemophilia products. These innovative treatments often come with a premium price tag, making them financially out of reach for both individuals and healthcare systems in resource-limited settings. Limited insurance coverage and public funding further exacerbate this issue, leaving many patients with traditional and less effective treatment options.

Additionally, the infrastructure required to support the administration and monitoring of advanced hemophilia treatments is often lacking in developing countries. This includes not only the availability of specialized medical personnel but also access to diagnostic facilities and transportation for patients who need regular care. Without the necessary infrastructure, the implementation of advanced therapies becomes a formidable challenge.

Key Market Trends

Collaborative Research and Drug Development

Pharmaceutical companies have the resources and expertise to develop and manufacture novel therapies. Research institutions contribute scientific knowledge and innovation, while patient organizations provide insights into the lived experiences of individuals with hemophilia. By working together, these entities can combine their strengths to tackle complex challenges. Collaborations enable researchers to pool their knowledge and data, expediting the research process. This can lead to quicker identification of potential drug candidates, streamlined clinical trials, and faster regulatory approvals. Patient organizations represent the voices and needs of individuals living with hemophilia. Their involvement ensures that new treatments are designed with patient preferences in mind, enhancing treatment adherence and overall satisfaction.

Collaborations can facilitate patient access to clinical trials of experimental treatments. Patient organizations often play a crucial role in connecting eligible individuals with these opportunities, ensuring that clinical trial participants are representative of the patient population.

Gene Therapy Advancements

Gene therapy for hemophilia is a promising and groundbreaking area of research that holds the potential to revolutionize the treatment landscape for individuals with hemophilia. This innovative approach aims to address the root cause of the condition by introducing functional clotting factor genes into a patient's body. As gene therapy techniques become more refined and successful, they offer the possibility of not just managing hemophilia but potentially curing it, eliminating the lifelong need for clotting factor infusions. Unlike traditional treatments that manage symptoms, gene therapy seeks to modify the underlying genetic defect responsible for hemophilia. By introducing functional clotting factor genes into the body, it has the potential to restore the ability to produce clotting factors naturally. Gene therapy offers the possibility of a preventive approach to hemophilia, where patients may no longer need to worry about bleeding episodes and can lead more normal, active lives.

While gene therapy for hemophilia holds immense promise, there are still challenges to overcome, including long-term safety and durability of the treatment effects, broader accessibility, and potential immune responses to the gene therapy vectors. However, ongoing research and development efforts are aimed at addressing these challenges, and the potential for a cure for hemophilia through gene therapy is an exciting prospect that offers hope to individuals and families affected by this rare bleeding disorder.

Segmental Insights

Type Insights

In 2022, Hemophilia A emerged as the dominant player in the hemophilia market, capturing the highest share. This genetic disorder is characterized by a deficiency in blood clotting factor VIII, leading to prolonged bleeding episodes. The prevalence of hemophilia A in developed regions, coupled with supportive government initiatives, has been instrumental in driving its market dominance. Major markets such as the U.S., Europe, and Japan have witnessed the launch of innovative products, further bolstering the market position of Hemophilia A. According to a survey conducted by the World Federation of Hemophilia (WFH) in 2020, countries like the U.S., India, and Brazil have reported a significant number of Hemophilia A cases, estimated to be around 10,000. This underscores the pressing need for effective treatment and management strategies to address this complex genetic disorder.

On the other hand, Hemophilia B is expected to exhibit steady growth during the forecast period. This variant of hemophilia is characterized by a deficiency in blood clotting factor IX. The market growth of Hemophilia B can be attributed to a robust pipeline of innovative products and the advent of gene therapy. Notably, in February 2023, the European Commission granted conditional approval to CSL Behring's gene therapy Hemgenix for the treatment of Hemophilia B. This milestone approval follows the product's successful launch in the U.S. market, where it is available at a price point of USD 3.5 million for a one-time treatment. These advancements in the treatment landscape hold promising prospects for individuals living with hemophilia, offering them improved quality of life and enhanced disease management options.

Treatment Insights

Based on the type of treatment, the treatment and hemophilia market is divided into two main categories: prevention and on-demand treatment. On-demand treatment, which involves administering medication when bleeding episodes occur, held the largest market share in 2022. However, the prevention segment is expected to experience the highest growth rate during the forecast period.

One commonly used and widely accepted form of preventive treatment is prophylaxis, which involves regular injections of coagulation factor concentrate. Prophylaxis has shown significant efficacy in managing severe hemophilia and has the potential to improve the growth rate of this market. The duration of prophylactic treatment varies depending on the severity of the patient's condition, and it aims to reduce productivity losses and enhance the overall quality of life for individuals with hemophilia.

By providing a consistent and proactive approach to managing bleeding episodes, prophylactic treatment holds promise in minimizing the impact of hemophilia on patients' daily lives. Its ability to prevent or reduce bleeding episodes not only improves physical well-being but also positively impacts emotional and social aspects of life for individuals living with this condition.

Regional Insights

In 2022, North America emerged as the dominant force in the global hemophilia treatment market, closely followed by Europe. The prevalence of hemophilia stands at approximately 134 cases per one million males in the United States. Factors such as the increasing prevalence of hemophilia, rising healthcare expenditure, growing awareness about bleeding disorders, extensive research and development in diagnostic technology and treatment, and favorable reimbursement policies contribute significantly to the growth of the hemophilia treatment market in North America. Looking ahead, Asia Pacific is projected to experience the highest growth rate in the forecast period of 2024-2028. The region's growth can be attributed to the rising incidence of hemophilia, increasing awareness about the disease, higher disposable income, and improving healthcare infrastructure. Notably, emerging economies like China and India are witnessing increased government and research institute funding for advancements in diagnostics and treatment of hemophilia, along with a growing utilization of recombinant products. These factors collectively present lucrative opportunities for the Asia Pacific market.

Key Market Players

  • Bayer AG
  • BioMarin Pharmaceutical, Inc.
  • CSL Behring LLC
  • Kedrion S.p.A
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Octapharma AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company
  • Grifols SA

Report Scope:

In this report, the Global Haemophilia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Haemophilia Treatment Market, By Type:

  • Haemophilia A
  • Haemophilia B
  • Haemophilia C

Haemophilia Treatment Market, By Product:

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrate
  • Desmopressin
  • Antifibrinolytics Agents

Haemophilia Treatment Market, By Treatment:

  • On-demand
  • Prophylaxis

Haemophilia Treatment Market, By Therapy:

  • Replacement Therapy
  • ITI therapy
  • Gene Therapy

Haemophilia Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Haemophilia Treatment Market.

Available Customizations:

  • Global Haemophilia Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Haemophilia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Haemophilia A, Haemophilia B, Haemophilia C)
    • 5.2.2. By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)
    • 5.2.3. By Treatment (On-demand and Prophylaxis)
    • 5.2.4. By Therapy (Replacement Therapy, ITI therapy and Gene Therapy)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Haemophilia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Treatment
    • 6.2.4. By Therapy
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Haemophilia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Treatment
        • 6.3.1.2.4. By Therapy
    • 6.3.2. Canada Haemophilia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Treatment
        • 6.3.2.2.4. By Therapy
    • 6.3.3. Mexico Haemophilia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Treatment
        • 6.3.3.2.4. By Therapy

7. Europe Haemophilia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Treatment
    • 7.2.4. By Therapy
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Haemophilia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Treatment
        • 7.3.1.2.4. By Therapy
    • 7.3.2. United Kingdom Haemophilia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Treatment
        • 7.3.2.2.4. By Therapy
    • 7.3.3. Italy Haemophilia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Treatment
        • 7.3.3.2.4. By Therapy
    • 7.3.4. France Haemophilia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Treatment
        • 7.3.4.2.4. By Therapy
    • 7.3.5. Spain Haemophilia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Treatment
        • 7.3.5.2.4. By Therapy

8. Asia-Pacific Haemophilia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Treatment
    • 8.2.4. By Therapy By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Haemophilia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Treatment
        • 8.3.1.2.4. By Therapy
    • 8.3.2. India Haemophilia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Treatment
        • 8.3.2.2.4. By Therapy
    • 8.3.3. Japan Haemophilia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Treatment
        • 8.3.3.2.4. By Therapy
    • 8.3.4. South Korea Haemophilia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Treatment
        • 8.3.4.2.4. By Therapy
    • 8.3.5. Australia Haemophilia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Treatment
        • 8.3.5.2.4. By Therapy

9. South America Haemophilia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Treatment
    • 9.2.4. By Therapy By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Haemophilia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Treatment
        • 9.3.1.2.4. By Therapy
    • 9.3.2. Argentina Haemophilia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Treatment
        • 9.3.2.2.4. By Therapy
    • 9.3.3. Colombia Haemophilia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Treatment
        • 9.3.3.2.4. By Therapy

10. Middle East and Africa Haemophilia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Treatment
    • 10.2.4. By Therapy
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Haemophilia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Treatment
        • 10.3.1.2.4. By Therapy
    • 10.3.2. Saudi Arabia Haemophilia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Treatment
        • 10.3.2.2.4. By Therapy
    • 10.3.3. UAE Haemophilia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Treatment
        • 10.3.3.2.4. By Therapy

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Haemophilia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Bayer AG
    • 15.5.2. BioMarin Pharmaceutical, Inc.
    • 15.5.3. CSL Behring LLC
    • 15.5.4. Kedrion S.p.A
    • 15.5.5. Novo Nordisk A/S
    • 15.5.6. Pfizer, Inc.
    • 15.5.7. Octapharma AG
    • 15.5.8. Sanofi S.A.
    • 15.5.9. Takeda Pharmaceutical Company
    • 15.5.10. Grifols SA

16. Strategic Recommendations

17. About Us & Disclaimer